Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials

3465 results

Sort By:

Alpha-Stim AID® Together With Life Coaching for the Support of Burnout Symptoms in Healthcare Workers

Study ID: NCT06977503
Start Date: 2025-10-15
End Date: 2027-05-15
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

40

Intervention / Treatment

Cranial Electrical Stimulation

Discussion

Health and Wellness Coach

Informational Intervention

Sham Intervention

Survey Administration

Sponsor

Roswell Park Cancer Institute

Source: clinicaltrials.gov

Share:
Add to list

A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia

Study ID: NCT07107334
Start Date: 2025-11
End Date: 2029-11
Study Type

Interventional

Study Phase

Phase2

No. of Participants

30

Intervention / Treatment

Glucagon-like peptide 1 receptor agonist

Sponsor

University of Florida

Source: clinicaltrials.gov

Share:
Add to list

A Study on a New Tetravalent Dengue Vaccine (TDV) Formulation in Healthy Adults

Study ID: NCT07047521
Start Date: 2025-11-17
End Date: 2027-07-30
Study Type

Interventional

Study Phase

Phase3

No. of Participants

496

Intervention / Treatment

Tetravalent Dengue Vaccine (TDV)

Sponsor

Takeda

Source: clinicaltrials.gov

Share:
Add to list

Online Intervention To Improve Motivation

Study ID: NCT07157293
Start Date: 2025-11
End Date: 2028-08
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

60

Intervention / Treatment

Online Motivation Enhancing Intervention

Sponsor

University of Alabama at Birmingham

Source: clinicaltrials.gov

Share:
Add to list

Connecting People With Cancer to Employment Support

Study ID: NCT07027449
Start Date: 2028-01
End Date: 2029-06
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

70

Intervention / Treatment

Screening and Referral Workflow

Sponsor

University of Kansas Medical Center

Source: clinicaltrials.gov

Share:
Add to list

CBD for Breast Cancer Primary Tumors

Study ID: NCT06148038
Start Date: 2026-03-01
End Date: 2028-01-01
Study Type

Interventional

Study Phase

Phase1

No. of Participants

60

Intervention / Treatment

CBD Oral

Control

Sponsor

Medical University of South Carolina

Source: clinicaltrials.gov

Share:
Add to list

Release Kinetics of rhBMP-2 Using E-PRF as an Autologous Carrier: An In Vitro Analysis

Study ID: NCT04670965
Start Date: 2025-12
End Date: 2027-07
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

20

Intervention / Treatment

E-PRF/rhBMP-2 (similar ratios)

E-PRF/ACS/rhBMP-2

rhBMP-2/E-PRF

E-PRF only

Sponsor

University of Alabama at Birmingham

Source: clinicaltrials.gov

Share:
Add to list

A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy

Study ID: NCT07091019
Start Date: 2025-11-15
End Date: 2033-05-15
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

1000

Intervention / Treatment

TKIs

Sponsor

Novartis Pharmaceuticals

Source: clinicaltrials.gov

Share:
Add to list

Ulonivirine (MK-8507) in Participants With Mild or Moderate Hepatic Impairment (MK-8507-014)

Study ID: NCT05093972
Start Date: 2026-04-07
End Date: 2026-09-10
Study Type

Interventional

Study Phase

Phase1

No. of Participants

22

Intervention / Treatment

Ulonivirine

Sponsor

Merck Sharp & Dohme LLC

Source: clinicaltrials.gov

Share:
Add to list

TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Study ID: NCT07190300
Start Date: 2025-11-03
End Date: 2032-05-14
Study Type

Interventional

Study Phase

Phase2

No. of Participants

203

Intervention / Treatment

Tulimimetostat

Darolutami

Abiraterone

Sponsor

Novartis Pharmaceuticals

Source: clinicaltrials.gov

Share:
Add to list